Changes in Hong Kong stocks | Binshi International (01705) rose more than 20% in early trading, and the company received a full purchase from China Biopharmaceuticals as the first consortium

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Binshi International (01705) rose more than 20% in early trading. As of press release, it rose 11.11% to HK$1.7, with a turnover of HK$17.7797 million.

According to the news, Binshi International announced that the offender plans to acquire 300 million shares, accounting for 75% of the total number of issued shares. The maximum total cash cost is HK$289 million, which is equivalent to the offer price of about HK$0.9634 per share, a discount of about 37.03% from the closing price of $1.53 on October 29. The offeror or the person acting in concert with the offeror buys all the issued shares as usual.

The announcement stated that the offender intends to maintain the listed status of the shares on the Stock Exchange after the end of the offer. The offenders are Time Innovation Global Limited and EJO Investment Pte. held by Xie Chengrun, executive director and CEO of China Biopharmaceuticals (01177), and Zheng Xiangling, vice chairman. Ltd.'s consortium.